We studied the effects of dihydroquercetin (3.3.4.5.7-pentahydroxyflavanone, a new Russian patented preparation) on functional activity of polymorphonuclear neutrophils from patients with non-insulin-dependent diabetes mellitus. Flavonoids (quercetin and its derivative dihydroquercetin) dose-dependently suppressed generation of anion radicals and hypochlorous acid and production of malonic dialdehyde during oxidation of neutrophil membranes. Dihydroquercetin decreased activities of protein kinase C and myeloperoxidase in activated polymorphonuclear neutrophils and could bind transition metals (Fe2+). These properties determine the ability of dihydroquercetin to decrease in vitro functional activity of polymorphonuclear neutrophils from patients with non-insulin-dependent diabetes mellitus.
Hepatocellular carcinoma is generally diagnosed at a late stage, which makes surgical treatment difficult. According to the Barcelona Clinic Liver Cancer (BCLC) staging system, patients with inoperable tumors can undergo transarterial chemoembolization or palliative therapy with sorafenib, their response rate does not exceed 30%. At the same time, the results of transarterial radioembolization (TARE) using yttrium-90-containing microspheres demonstrate an optimistic picture. In this paper, the authors systematize from expert positions the current data from the literature on the use of TARE to treat liver cancer in clinical practice and formulate prospects for using the technique in the Russian Federation. Based on the literature data, the authors demonstrate the superiority of TARE over sorafenib therapy and the results that are comparable with chemoembolization.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.